Cytovir ADV

N/A

Report date: 2022/09/06 16:40:24

Base Information

Drug NameCytovir ADV

Drug Alias NameAdenovirus-specific T cell therapy (Kuur Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionImmunostimulantsT lymphocyte replacementsImmunologic cytotoxicity +[4]

TargetsNot applicable

Therapy Area/IndicationsCytomegalovirus InfectionsAdenoviridae Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity College London Cell Medica Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCell Medica Ltd

Active IndicationsN/A

Inactive IndicationsCytomegalovirus InfectionsAdenoviridae Infections

Other Information

ATC CodeN/A